AstraZeneca Pharma India Limited announced that Bhavana Agrawal, Executive Director and Chief Financial Officer, has submitted her resignation from the CFO role with effect from the close of business on August 31, 2026. The move comes as she takes up a regional role within the AstraZeneca Group, signaling an internal reshuffle rather than an exit from the company.
Her departure marks a significant moment for the Indian arm of the multinational as it plots a course through leadership continuity in finance. With the CFO seat to be vacated, AstraZeneca Pharma India will oversee a transition while continuing to execute on its strategic priorities across the business.
Agrawal has been a central figure in steering financial strategy, governance and reporting through a pivotal phase of the business. The company will coordinate the transition as it ensures continuity in its financial leadership.
Within AstraZeneca Group, internal mobility underscores a broader trend of cross-border assignments designed to leverage expertise and align regional needs with group-wide objectives.